ARTICLE | Clinical News

AstraZeneca preclinical data

November 9, 2009 8:00 AM UTC

In rats, a single dose of aerosolized motavizumab administered 24 hours prior to intranasal infection with RSV subtype A2 significantly decreased lung viral titers vs. control antibody. Data were presented at the Infectious Disease Society of America meeting in Philadelphia. ...